Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation最新文献

{"title":"Inhaled Corticosteroids and Risk of Cardiovascular Disease in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Regression.","authors":"Krish Gadhvi,&nbsp;Minnah Kandeil,&nbsp;Dinushan Raveendran,&nbsp;Jeewoo Choi,&nbsp;Nia Davies,&nbsp;Anya Nanchahal,&nbsp;Oliva Wing,&nbsp;Jennifer Quint,&nbsp;Hannah Whittaker","doi":"10.15326/jcopdf.2022.0386","DOIUrl":"https://doi.org/10.15326/jcopdf.2022.0386","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have reported mixed associations between inhaled corticosteroids (ICSs) and cardiovascular disease (CVD) in people with chronic obstructive pulmonary disease (COPD). Using updated literature, we investigated the association between ICS-containing medications and CVD in COPD patients, stratified by study-related factors.</p><p><strong>Methods: </strong>We searched MEDLINE and EMBASE for studies that reported effect estimates for the association between ICS-containing medications and the risk of CVD in COPD patients. CVD outcomes specifically included heart failure, myocardial infarction, and stroke-related events. We conducted a random-effects meta-analysis and a meta-regression to identify effect-modifying study-related factors.</p><p><strong>Results: </strong>Fifteen studies met inclusion criteria and investigated the association between ICS-containing medications and the risk of CVD. Pooled results from our meta-analysis showed a significant association between ICS-containing medication and reduced risk of CVD (hazard ratio 0.87, 95% confidence intervals 0.78 to 0.97). Study follow-up time, non-ICS comparator, and exclusion of patients with previous CVD modified the association between ICS use and risk of CVD.</p><p><strong>Conclusions: </strong>Overall, we found an association between ICS-containing medications and reduced risk of CVD in COPD patients. Results from the meta-regression suggest that subgroups of COPD patients may benefit from ICS use more than others and further work is needed to determine this.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484493/pdf/JCOPDF-10-317.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Bronchiectasis on COPD Severity and Alpha-1 Antitrypsin Deficiency as a Risk Factor in Individuals with a Heavy Smoking History.","authors":"Manuel Izquierdo, Chad R Marion, Frank Genese, John D Newell, Wanda K O'Neal, Xingnan Li, Gregory A Hawkins, Igor Barjaktarevic, R Graham Barr, Stephanie Christenson, Christopher B Cooper, David Couper, Jeffrey Curtis, Meilan K Han, Nadia N Hansel, Richard E Kanner, Fernando J Martinez, Robert Paine, Vickram Tejwani, Prescott G Woodruff, Joe G Zein, Eric A Hoffman, Stephen P Peters, Deborah A Meyers, Eugene R Bleecker, Victor E Ortega","doi":"10.15326/jcopdf.2023.0388","DOIUrl":"10.15326/jcopdf.2023.0388","url":null,"abstract":"<p><strong>Rationale: </strong>Bronchiectasis is common among those with heavy smoking histories, but risk factors for bronchiectasis, including alpha-1 antitrypsin deficiency, and its implications for COPD severity are uncharacterized in such individuals.</p><p><strong>Objectives: </strong>To characterize the impact of bronchiectasis on COPD and explore alpha-1antitrypsin as a risk factor for bronchiectasis.</p><p><strong>Methods: </strong>SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS) participants (N=914; ages 40-80 years; ≥20-pack-year smoking) had high-resolution computed tomography (CT) scans interpreted visually for bronchiectasis, based on airway dilation without fibrosis or cicatrization. We performed regression-based models of bronchiectasis with clinical outcomes and quantitative CT measures. We deeply sequenced the gene encoding -alpha-1 antitrypsin, <i>SERPINA1</i>, in 835 participants to test for rare variants, focusing on the PiZ genotype (Glu³⁶⁶Lys, rs28929474).</p><p><strong>Measurements and main results: </strong>We identified bronchiectasis in 365 (40%) participants, more frequently in women (45% versus 36%, <i>p</i>=0.0045), older participants (mean age=66[standard deviation (SD)=8.3] versus 64[SD=9.1] years, <i>p</i>=0.0083), and those with lower lung function (forced expiratory volume in 1 second [FEV₁ ] percentage predicted=66%[SD=27] versus 77%[SD=25], <i>p</i><0.0001; FEV₁ to forced vital capacity [FVC] ratio=0.54[0.17] versus 0.63[SD=0.16], <i>p</i><0.0001). Participants with bronchiectasis had greater emphysema (%voxels ≤-950 Hounsfield units, 11%[SD=12] versus 6.3%[SD=9], <i>p</i><0.0001) and parametric response mapping functional small airways disease (26[SD=15] versus 19[SD=15], <i>p</i><0.0001). Bronchiectasis was more frequent in the combined PiZZ and PiMZ genotype groups compared to those without PiZ, PiS, or other rare pathogenic variants (N=21 of 40 [52%] versus N=283 of 707[40%], odds ratio [OR]=1.97; 95% confidence interval [CI]=1.002, 3.90, <i>p</i>=0.049), an association attributed to White individuals (OR=1.98; 95%CI = 0.9956, 3.9; <i>p</i>=0.051).</p><p><strong>Conclusions: </strong>Bronchiectasis was common in those with heavy smoking histories and was associated with detrimental clinical and radiographic outcomes. Our findings support alpha-1antitrypsin guideline recommendations to screen for alpha-1 antitrypsin deficiency in an appropriate bronchiectasis subgroup with a significant smoking history.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484491/pdf/JCOPDF-10-199.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Marijuana Smoking on COPD Progression in a Cohort of Middle-Aged and Older Persons.","authors":"Igor Barjaktarevic, Christopher B Cooper, Tracie Shing, Russell G Buhr, Eric A Hoffman, Prescott G Woodruff, M Bradley Drummond, Richard E Kanner, MeiLan K Han, Nadia N Hansel, Russell P Bowler, Gregory L Kinney, Sean Jacobson, Madeline A Morris, Fernando J Martinez, Jill Ohar, David Couper, Donald P Tashkin","doi":"10.15326/jcopdf.2022.0378","DOIUrl":"10.15326/jcopdf.2022.0378","url":null,"abstract":"<p><strong>Background: </strong>Limited data are available regarding marijuana smoking's impact on the development or progression of chronic obstructive pulmonary disease (COPD) in middle-aged or older adults with a variable history of tobacco cigarette smoking.</p><p><strong>Methods: </strong>We divided ever-tobacco smoking participants in the SubPopulations and InteRmediate Outcomes In COPD Study (SPIROMICS) into 3 groups based on self-reported marijuana use: current, former, or never marijuana smokers (CMSs, FMSs or NMSs, respectively). Longitudinal data were analyzed in participants with ≥2 visits over a period of ≥52 weeks.</p><p><strong>Measurements: </strong>We compared CMSs, FMSs, and NMSs, and those with varying amounts of lifetime marijuana use. Mixed effects linear regression models were used to analyze changes in spirometry, symptoms, health status, and radiographic metrics; zero-inflated negative binomial models were used for exacerbation rates. All models were adjusted for age, sex, race, baseline tobacco smoking amount, and forced expiratory volume in 1 second (FEV₁) %predicted.</p><p><strong>Results: </strong>Most participants were followed for ≥4 years. Annual rates of change in FEV₁, incident COPD, respiratory symptoms, health status, radiographic extent of emphysema or air trapping, and total or severe exacerbations were not different between CMSs or FMSs versus NMSs or between those with any lifetime amount of marijuana use versus NMSs.</p><p><strong>Conclusions: </strong>Among SPIROMICS participants with or without COPD, neither former nor current marijuana smoking of any lifetime amount was associated with evidence of COPD progression or its development. Because of our study's limitations, these findings underscore the need for further studies to better understand longer-term effects of marijuana smoking in COPD.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484485/pdf/JCOPDF-10-234.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreased Cardiac Autonomic Function is Associated with Higher Exacerbation Risk and Symptom Burden in Chronic Obstructive Pulmonary Disease.","authors":"Sarath Raju, Han Woo, Ashraf Fawzy, Nirupama Putcha, Aparna Balasubramanian, Stephen C Mathai, Ronald D Berger, Nadia N Hansel, Meredith C McCormack","doi":"10.15326/jcopdf.2023.0410","DOIUrl":"10.15326/jcopdf.2023.0410","url":null,"abstract":"<p><p>Current measures of chronic obstructive pulmonary disease (COPD) severity, including lung function, do not fully explain symptom burden, and there is a need to identify predictors of exacerbation risk and morbidity. Autonomic dysfunction may be implicated in both cardiovascular and respiratory morbidity in COPD and convey risk for exacerbations. Heart rate variability (HRV) is a marker of cardiac autonomic function that is predictive of cardiovascular health and has promise as a non-invasive COPD biomarker. The CLEAN AIR Heart study provided an opportunity to investigate the association between HRV and COPD morbidity among former smokers with moderate-severe COPD. Eighty-five participants, contributing 305 HRV measurements, underwent repeated clinical assessments over 4 study periods that included a 24-Holter monitoring assessment of HRV. HRV measures of interest were standard deviation of normal-to-normal intervals, (SDNN) (overall HRV) and root-mean-square of successive differences (RMSSD) (parasympathetic function). Exacerbation risk was assessed using negative binomial models, and mixed-effects models analyzed associations between HRV and symptoms. Decreases in SDNN (incidence rate ratio [IRR]1.40; 95% confidence interval [CI] 1.13 to1.74) and RMSSD (IRR 1.60; 95% CI 1.07 to 2.37) were associated with severe exacerbation risk. Decreases in SDNN were associated with higher St George's Respiratory Questionnaire scores, COPD Assessment Test scores, and chronic bronchitis symptoms. Findings demonstrate that HRV is associated with COPD symptom burden and exacerbation risk. HRV may represent an important biomarker with the potential to identify high-risk COPD populations.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484486/pdf/JCOPDF-10-328.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10175603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of Smoking, Cytomegalovirus Serostatus, and Natural Killer Cell Phenotypes in Smokers With and At Risk for COPD.","authors":"Robert M Burkes,&nbsp;Elijah Bailey,&nbsp;Timothy Hwalek,&nbsp;Andrew Osterburg,&nbsp;Laura Lach,&nbsp;Ralph Panos,&nbsp;Stephen N Waggoner,&nbsp;Michael T Borchers","doi":"10.15326/jcopdf.2022.0382","DOIUrl":"https://doi.org/10.15326/jcopdf.2022.0382","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic obstructive disease (COPD) risk factors, smoking, and chronic infection (cytomegalovirus [CMV]) may mold natural killer (NK) cell populations. What is not known is the magnitude of the effect CMV seropositivity imparts on populations of smokers with and at risk for COPD. We investigate the independent influence of CMV seropositivity on NK cell populations and differential effects when stratifying by COPD and degree of smoking history.</p><p><strong>Methods: </strong>Descriptive statistics determine the relationship between cytotoxic NK cell populations and demographic and clinical variables. Multivariable linear regression and predictive modeling were performed to determine associations between positive CMV serology and proportions of CD57+ and natural killer group 2C (NKG2C)+ NK cells. We dichotomized our analysis by those with a heavy smoking history and COPD and described the effect size of CMV seropositivity on NK cell populations.</p><p><strong>Results: </strong>When controlled for age, race, sex, pack-years smoked, body mass index, and lung function, CMV+ serostatus was independently associated with a higher proportion of CD57+, NKG2C+, and NKG2C+CD57+ NK cells. CMV+ serostatus was the sole predictor of larger NKG2C+ and CD57+NKG2C+ populations. Associations are more pronounced in those with COPD and heavy smokers.</p><p><strong>Conclusions: </strong>Among Veterans who are current and former smokers, CMV+ serostatus was independently associated with larger CD57+ and NKG2C+ populations, with a larger effect in heavy smokers and those with COPD, and was the sole predictor for increased expression of NKG2C+ and CD57+NKG2C+ populations. These findings may be broadened to include the assessment of longitudinal NK cell population change, accrued inflammatory potential, and further identification of pro-inflammatory NK cell population clusters.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484488/pdf/JCOPDF-10-286.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10182549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Communication Instrument to Address Sexuality in COPD: COSY.","authors":"Claudia Steurer-Stey,&nbsp;Kaba Dalla Lana,&nbsp;Alexandra Strassmann,&nbsp;Stefanie Gonin-Spahni,&nbsp;Michelle Borgmann,&nbsp;Ursina Brun Del Re,&nbsp;Sebastian Haas,&nbsp;Eliane Sarasin,&nbsp;Andrea Burri,&nbsp;Anja Frei,&nbsp;Milo A Puhan","doi":"10.15326/jcopdf.2022.0355","DOIUrl":"https://doi.org/10.15326/jcopdf.2022.0355","url":null,"abstract":"<p><strong>Introduction: </strong>Sexuality, an important aspect of quality of life, is often overlooked in COPD. Our aim was to develop an instrument that facilitates communication and counseling on sexuality in persons living with chronic obstructive pulmonary disease (COPD).</p><p><strong>Methods: </strong>We searched for publications on sexuality in COPD focusing on communication about sexuality and tools to support such communication. We also performed a survey asking 25 patients and 36 health care professionals (HCPs) about their attitudes, experiences, barriers, and facilitators when talking about sexuality. We set up a project expert team of HCPs and 3 persons with COPD. In a half-day workshop, the team discussed the results of the literature review and the survey as a basis for the contents, the \"when and how\" to address communication about sexuality, and the design of the communication instrument.</p><p><strong>Results: </strong>The survey showed that although patients and HCPs wanted to talk about sexuality, it rarely happened due to communication barriers, lack of self-confidence, and misconceptions on both sides. In review rounds of the expert team, feedback on the drafts was collected and integrated into the final version of the communication instrument: COmmunication about SexualitY in COPD (COSY). The COSY instrument resulted in 4 tools: a communication leaflet, an application guide, a pictorial representation of the spectrum of intimacy for HCPs, and a comprehensible, picturized information booklet for patients.</p><p><strong>Conclusions: </strong>Addressing sexuality in persons living with COPD should not be neglected. The COSY instrument could help to start and shape communication and consultations about sexuality and a more holistic consideration of quality of life.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392872/pdf/JCOPDF-10-148.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9919307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Between Systemic Arterial Hypertension and Chronic Obstructive Pulmonary Disease. Results from the U.S. National Health and Nutrition Examination Survey 1999-2018: A Cross-sectional Study.","authors":"Xiaopeng Liang,&nbsp;Oscar Hou In Chou,&nbsp;Bernard My Cheung","doi":"10.15326/jcopdf.2022.0306","DOIUrl":"https://doi.org/10.15326/jcopdf.2022.0306","url":null,"abstract":"<p><strong>Background: </strong>Systemic arterial hypertension (HTN) is one of the common comorbidities among patients with chronic obstructive pulmonary disease (COPD). This study aimed to investigate the association between HTN and COPD.</p><p><strong>Methods: </strong>A total of 46,804 eligible non-pregnant participants aged ≥ 20 years examined in the Mobile Examination Center of the National Health and Nutrition Examination Survey (NHANES) 1999-2018 were included in this cross-sectional study. Participants with invalid data on covariates, HTN, and COPD were excluded. The association between HTN and COPD was studied using logistic regression upon adjusting the potential covariates.</p><p><strong>Results: </strong>Among the participants, 46.1% (95% confidence interval [CI], 45.3-46.9) had HTN, and 6.8% (95% CI, 6.4-7.2) had self-reported COPD. COPD was associated with HTN (OR [odds ratio]=1.18, 95% CI [1.05-1.31], <i>P</i><0.01) after adjusting for demographics, socioeconomic factors, smoking, diabetes, body mass index, and medication use, including inhaled corticosteroids and methylxanthines. The association between HTN and COPD was significant among adults younger than 60 years (<i>P</i><0.01). Stratified by smoking status, there was a significant association between HTN and COPD in current heavy smokers (1.25, 95% CI [1.01-1.58]; <i>P</i>=0.04).</p><p><strong>Conclusions: </strong>In this nationwide survey, COPD was associated with HTN. The association was more robust among adults younger than 60 years and current heavy smokers. Future prospective studies are needed to examine the relationship between HTN and COPD.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392877/pdf/JCOPDF-10-190.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10279818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated with Attrition in a Longitudinal Cohort of Older Adults in the Community.","authors":"Noah Katsuno,&nbsp;Pei Z Li,&nbsp;Jean Bourbeau,&nbsp;Shawn Aaron,&nbsp;Francois Maltais,&nbsp;Paul Hernandez,&nbsp;Kenneth R Chapman,&nbsp;Brandie Walker,&nbsp;Darcy D Marciniuk,&nbsp;Denis D ODonnell,&nbsp;Don D Sin,&nbsp;James C Hogg,&nbsp;Michael Cheng,&nbsp;Jeremy Road,&nbsp;Wan C Tan","doi":"10.15326/jcopdf.2022.0380","DOIUrl":"https://doi.org/10.15326/jcopdf.2022.0380","url":null,"abstract":"<p><strong>Introduction: </strong>Retaining participants in longitudinal studies increases their power. We undertook this study in a population-based longitudinal cohort of adults with COPD to determine the factors associated with increased cohort attrition.</p><p><strong>Methods: </strong>In the longitudinal population-based Canadian Cohort of Obstructive Lung Disease (CanCOLD) study, 1561 adults > 40 years old were randomly recruited from 9 urban sites. Participants completed in-person visits at 18-month intervals and also were followed up every 3 months over the phone or by email. The cohort retention for the study and the reasons for attrition were analyzed. Hazard ratios and robust standard errors were calculated using Cox regression methods to explore the associations between participants who remained in the study and those who did not.</p><p><strong>Results: </strong>The median follow-up (years) of the study is 9.0 years. The overall mean retention was 77%. Reasons for attrition (23%) were: dropout by participant (39%), loss of contact (27%), investigator-initiated withdrawal (15%), deaths (9%), serious disease (9%), and relocation (2%). Factors independently associated with attrition were lower educational attainment, higher pack-year tobacco consumption, diagnosed cardiovascular disease, and a higher Hospital Anxiety and Depression Scale score: adjusted hazard ratios (95% confidence interval) were 1.43(1.11, 1.85); 1.01(1.00, 1.01); 1.44(1.13, 1.83); 1.06(1.02, 1.10) respectively.</p><p><strong>Conclusions: </strong>Identification and awareness of risk factors for attrition could direct targeted retention strategies in longitudinal studies. Moreover, the identification of patient characteristics associated with study dropout could address any potential bias introduced by differential dropouts.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392873/pdf/JCOPDF-10-178.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9925618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life and Mortality Outcomes for Augmentation Naïve and Augmented Patients with Severe Alpha-1 Antitrypsin Deficiency.","authors":"Paul R Ellis,&nbsp;Kristen E Holm,&nbsp;Radmila Choate,&nbsp;David M Mannino,&nbsp;Robert A Stockley,&nbsp;Robert A Sandhaus,&nbsp;Alice M Turner","doi":"10.15326/jcopdf.2022.0339","DOIUrl":"https://doi.org/10.15326/jcopdf.2022.0339","url":null,"abstract":"<p><strong>Background: </strong>Intravenous alpha-1 antitrypsin (AAT) augmentation therapy is the only specific treatment available for alpha-1 antitrypsin deficiency (AATD)-related lung disease. It is widely used worldwide but remains unavailable to patients with AATD in the United Kingdom. While randomized trials of augmentation therapy have demonstrated biochemical efficacy and lung tissue preservation using computed tomography (CT) densitometry, these studies were not adequately powered to demonstrate effectiveness in well-accepted clinical endpoints such as quality of life (QOL) or survival. We used large, prospectively followed AATD patient populations in the United States and United Kingdom to explore these important clinical endpoints.</p><p><strong>Methods: </strong>Our inclusion criterion was adults with severe AATD and associated lung disease. The treatment group was U.S. AATD patients receiving augmentation therapy for lung disease. The control group was augmentation therapy naïve AATD patients. Multivariable regression and survival analyses were used to assess QOL and mortality outcomes respectively.</p><p><strong>Results: </strong>Mean annual deterioration of the St George's Respiratory Questionnaire total score was 1.43 points greater/year in the control group compared to those receiving augmentation therapy (95% confidence interval [CI] 0.47 to 2.39, <i>p</i>=0.003). At 7 years, median survival was 82.7% (95% CI 75.3 to 90.7) for the control group versus 87.8% (95% CI 82.8 to 93.2) in the augmentation group, <i>p</i>=0.66. There was significant heterogeneity between cohorts.</p><p><strong>Conclusions: </strong>A comparison of 2 highly characterized AATD cohorts was not able to reliably determine if AAT augmentation therapy improves QOL or mortality in patients with severe AATD-related lung disease. Alternative surrogate biomarkers of disease progression, such as CT lung density, may be a more pragmatic option.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392875/pdf/JCOPDF-10-139.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9976876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Airway and Systemic Prostaglandin E2 Association with COPD Symptoms and Macrophage Phenotype.","authors":"Vickram Tejwani,&nbsp;Andres F Villabona-Rueda,&nbsp;Pratik Khare,&nbsp;Cissy Zhang,&nbsp;Anne Le,&nbsp;Nirupama Putcha,&nbsp;Franco D'Alessio,&nbsp;Neil E Alexis,&nbsp;Nadia N Hansel,&nbsp;Ashraf Fawzy","doi":"10.15326/jcopdf.2022.0375","DOIUrl":"https://doi.org/10.15326/jcopdf.2022.0375","url":null,"abstract":"<p><strong>Background: </strong>Polymorphisms and products of the cyclooxygenase (COX) pathway have been associated with the development of chronic obstructive pulmonary disease (COPD) and adverse outcomes. COX-produced prostaglandin E2 (PGE-2) may play a role in the inflammation observed in COPD, potentially through deleterious airway macrophage polarization. A better understanding of the role of PGE-2 in COPD morbidity may inform trials for therapeutics targeting the COX pathway or PGE-2.</p><p><strong>Methods: </strong>Urine and induced sputum were collected from former smokers with moderate-severe COPD. The major urinary metabolite of PGE-2 (PGE-M) was measured, and ELISA was performed on sputum supernatant for PGE-2 airway measurement. Airway macrophages underwent flow cytometry phenotyping (surface CD64, CD80, CD163, CD206, and intracellular IL-1β, TGF-β1). Health information was obtained the same day as the biologic sample collection. Exacerbations were collected at baseline and then monthly telephone calls.</p><p><strong>Results: </strong>Among 30 former smokers with COPD (mean±SD age 66.4±8.88 years and forced expiratory volume in 1 second [FEV₁] 62.4±8.37 percent predicted), a 1 pg/mL increase in sputum PGE-2 was associated with higher odds of experiencing at least one exacerbation in the prior 12 months (odds ratio 3.3; 95% confidence interval: 1.3 to15.0), worse respiratory symptoms and health status. PGE-M was not associated with exacerbations or symptoms. Neither airway PGE-2 nor urinary PGE-M was uniformly associated with an M1 or M2 polarization.</p><p><strong>Conclusions: </strong>Elevated levels of sputum PGE-2, rather than systemic PGE-2, is associated with increased respiratory symptoms and history of exacerbation among individuals with COPD. Additional studies focused on mechanism of action are warranted.</p>","PeriodicalId":51340,"journal":{"name":"Chronic Obstructive Pulmonary Diseases-Journal of the Copd Foundation","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392871/pdf/JCOPDF-10-159.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10297826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}